Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Exclusion Criteria

• •Currently receiving an ART regimen other than \> or equal to two NRTIs and either LPV/r or FPV/r
• •Prior use of darunavir or atazanavir
• •CDC Class C Illness diagnosed within 30 days of screening
• •Patient is currently receiving the following Hydroxamethylglutaryl-coA (HMGCoA) reductase inhibitor medications (statins): pravastatin, lovastatin, simvastatin
• •Patient is currently receiving a bile acid sequestrant (cholestyramine, colestipol, and colesevelam)
• •Grade 3 or 4 Laboratory abnormalities as defined by a standardized grading scheme based on the DAIDS table with the following exceptions:
• •1. Pre-existing diabetes mellitus with asymptomatic, nonfasting glucose grade 3 elevations
• •2. Subjects with asymptomatic grade 3 fasting triglyceride or cholesterol elevations
• •Clinical or laboratory evidence of clinically significant liver impairment/dysfunction disease or cirrhosis
• •Note: Individuals co-infected with chronic hepatitis B or C viruses will be allowed to enter the trial if their condition is clinically stable and they will not require therapy during the course of the study. Individuals diagnosed with acute viral hepatitis at screening will not be allowed to enroll during acute phase
• •Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance
• •Use of any investigational agents 30 days prior to screening
• •Life expectancy \< 6 months in the opinion of the investigator
• •Pregnancy or breast feeding
• •Female subject of childbearing potential (i.e., heterosexually active, and not surgically sterile or at least two years post-menopausal) not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity